Acadia Healthcare Co., Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00404A1097
USD
13.23
-8.76 (-39.84%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Acadia Healthcare Co., Inc. stock-summary
stock-summary
Acadia Healthcare Co., Inc.
Pharmaceuticals & Biotechnology
Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities. The Company is engaged in operating acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers and facilities providing outpatient behavioral healthcare services. Its U.S. Facilities include approximately 224 behavioral healthcare facilities with approximately 9,500 beds in 40 states and Puerto Rico. The Company’s U.K. Facilities include approximately 361 behavioral healthcare facilities with approximately 8,700 beds in the United Kingdom. The Company operates a network of approximately 588 behavioral healthcare facilities with approximately 18,200 beds in 40 states, the United Kingdom and Puerto Rico.
Company Coordinates stock-summary
Company Details
6100 Tower Cir Ste 1000 , FRANKLIN TN : 37067-1509
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 91 Schemes (57.18%)

Foreign Institutions

Held by 162 Foreign Institutions (10.26%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Reeve Waud
Independent Chairman of the Board
Ms. Debra Osteen
Chief Executive Officer, Director
Mr. Jason Bernhard
Independent Director
Mr. E. Perot Bissell
Independent Director
Mr. Michael Fucci
Independent Director
Ms. Vicky Gregg
Independent Director
Mr. William Grieco
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
869 Million
(Quarterly Results - Jun 2025)
Net Profit:
38 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2,081 Million (Small Cap)

stock-summary
P/E

8.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.70

stock-summary
Return on Equity

8.80%

stock-summary
Price to Book

0.68